ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)

ClinicalTrials.gov ID: NCT03358576

Public ClinicalTrials.gov record NCT03358576. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 3:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Prospective, Phase 3, Randomized, Multi-center, Double-blind Study of Efiicacy, Tolerability & Safety of Sulopenem & Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro-metronidazole for Treatment of cIAI in Adults

Study identification

NCT ID
NCT03358576
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Iterum Therapeutics, International Limited
Industry
Enrollment
674 participants

Conditions and interventions

Interventions

  • Amoxicillin-Clavulanate Drug
  • Ciprofloxacin Drug
  • Ertapenem Drug
  • Metronidazole Drug
  • Sulopenem Drug
  • Sulopenem-Etzadroxil/Probenecid Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 17, 2018
Primary completion
Oct 1, 2019
Completion
Oct 1, 2019
Last update posted
Nov 30, 2020

2018 – 2019

United States locations

U.S. sites
12
U.S. states
9
U.S. cities
11
Facility City State ZIP Site status
Medical Facility Chula Vista California 91911
Medical Facility Torrance California 90509
Medical Facility Idaho Falls Idaho 83404
Medical Facility Boston Massachusetts 02111
Medical Facility Royal Oak Michigan 48073
Medical Facility St Louis Missouri 63110
Medical Facility Butte Montana 59701
Medical Facility Lincoln Nebraska 68510
Medical Facility Omaha Nebraska 68114
Medical Facility Somers Point New Jersey 08244
Medical Facility Columbus Ohio 43210
Medical Facility Columbus Ohio 43215

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03358576, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 30, 2020 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03358576 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →